Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 2
1989 3
1990 2
1991 1
1992 5
1993 2
1994 4
1995 7
1996 9
1997 9
1998 7
1999 11
2000 5
2001 1
2002 6
2003 9
2004 7
2005 27
2006 48
2007 70
2008 86
2009 101
2010 138
2011 139
2012 128
2013 146
2014 166
2015 176
2016 147
2017 152
2018 158
2019 193
2020 207
2021 213
2022 222
2023 242
2024 105

Text availability

Article attribute

Article type

Publication date

Search Results

2,572 results

Results by year

Filters applied: . Clear all
Page 1
NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
Qin G, Wang X, Ye S, Li Y, Chen M, Wang S, Qin T, Zhang C, Li Y, Long Q, Hu H, Shi D, Li J, Zhang K, Zhai Q, Tang Y, Kang T, Lan P, Xie F, Lu J, Deng W. Qin G, et al. Nat Commun. 2020 Apr 3;11(1):1669. doi: 10.1038/s41467-020-15364-z. Nat Commun. 2020. PMID: 32245950 Free PMC article.
Furthermore, we demonstrate that PARP1 suppresses PD-L1 transcription through its interaction with the nucleic acid binding domain of NPM1, which is required for the binding of NPM1 at PD-L1 promoter. Consistently, the PARP1 inhibitor olaparib elevates PD-L1 express …
Furthermore, we demonstrate that PARP1 suppresses PD-L1 transcription through its interaction with the nucleic acid binding domain of NPM …
NPM1-mutated acute myeloid leukemia: from bench to bedside.
Falini B, Brunetti L, Sportoletti P, Martelli MP. Falini B, et al. Blood. 2020 Oct 8;136(15):1707-1721. doi: 10.1182/blood.2019004226. Blood. 2020. PMID: 32609823 Free article. Review.
Because of its unique features, NPM1-mutated AML is recognized as a distinct entity in the 2017 World Health Organization (WHO) classification of hematopoietic neoplasms. ...The contribution of HOX genes' expression to the development of NPM1-mutated AML is a …
Because of its unique features, NPM1-mutated AML is recognized as a distinct entity in the 2017 World Health Organization (WHO) class …
The potential role of nucleophosmin (NPM1) in the development of cancer.
Karimi Dermani F, Gholamzadeh Khoei S, Afshar S, Amini R. Karimi Dermani F, et al. J Cell Physiol. 2021 Nov;236(11):7832-7852. doi: 10.1002/jcp.30406. Epub 2021 May 7. J Cell Physiol. 2021. PMID: 33959979 Review.
NPM1 has been identified to be necessary for normal cellular functions, and its altered regulation by overexpression, mutation, translocation, loss of function, or sporadic deletion can lead to cancer and tumorigenesis. In this review, we focus on the gene and prote …
NPM1 has been identified to be necessary for normal cellular functions, and its altered regulation by overexpression, mutation, trans …
NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS, Zhou LM, Yuan LL, Gao Y, Kui XY, Liu XY, Pei ZJ. Liu XS, et al. Front Immunol. 2021 Jul 16;12:724741. doi: 10.3389/fimmu.2021.724741. eCollection 2021. Front Immunol. 2021. PMID: 34335635 Free PMC article.
RESULTS: NPM1 was overexpressed in a variety of tumors including LUAD, and the ROC curve showed that NPM1 had a certain accuracy in predicting the outcome of tumors and normal samples. ...NPM1 can be used as an effective target for diagnosis and treatment of …
RESULTS: NPM1 was overexpressed in a variety of tumors including LUAD, and the ROC curve showed that NPM1 had a certain accura …
NPM1 promotes cell proliferation by targeting PRDX6 in colorectal cancer.
Wang D, Li Y, Liu Y, Cheng S, Liu F, Zuo R, Ding C, Shi S, Liu G. Wang D, et al. Int J Biochem Cell Biol. 2022 Jun;147:106233. doi: 10.1016/j.biocel.2022.106233. Epub 2022 Jun 1. Int J Biochem Cell Biol. 2022. PMID: 35659568
NPM1 is significantly overexpressed in a variety of tumors, including colorectal cancer, but its role and mechanism in colorectal cancer remain unknown. ...NPM1 and PRDX6 are potential colorectal cancer therapeutic targets....
NPM1 is significantly overexpressed in a variety of tumors, including colorectal cancer, but its role and mechanism in colorec …
Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.
Falini B, Dillon R. Falini B, et al. Blood Cancer Discov. 2024 Jan 8;5(1):8-20. doi: 10.1158/2643-3230.BCD-23-0144. Blood Cancer Discov. 2024. PMID: 37917833 Review.
NPM1-mutated acute myeloid leukemia (AML) represents the largest molecular subgroup of adult AML. ...Here, we review the criteria for appropriate diagnosis and molecular monitoring of NPM1-mutated AML. SIGNIFICANCE: NPM1-mutated AML represents a distinct enti …
NPM1-mutated acute myeloid leukemia (AML) represents the largest molecular subgroup of adult AML. ...Here, we review the criteria for …
NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.
Falini B. Falini B. Am J Hematol. 2023 Sep;98(9):1452-1464. doi: 10.1002/ajh.26989. Epub 2023 Jun 15. Am J Hematol. 2023. PMID: 37317978 Review.
Because of its unique molecular and clinico-pathological features, NPM1-mutated AML is regarded as a distinct leukemia entity in both the International Consensus Classification (ICC) and the 5th edition of the World Health Organization (WHO) classification of myeloid ne …
Because of its unique molecular and clinico-pathological features, NPM1-mutated AML is regarded as a distinct leukemia entity in both …
How I diagnose and treat NPM1-mutated AML.
Falini B, Brunetti L, Martelli MP. Falini B, et al. Blood. 2021 Feb 4;137(5):589-599. doi: 10.1182/blood.2020008211. Blood. 2021. PMID: 33171486 Free article.
NPM1-mutated AML exhibits unique molecular, pathological, and clinical features, which led to its recognition as distinct entity in the 2017 World Health Organization (WHO) classification of myeloid neoplasms. ...Moreover, the percentage of blasts required to diagno …
NPM1-mutated AML exhibits unique molecular, pathological, and clinical features, which led to its recognition as distinct entity in t …
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S, Yim S, Park H. Chang S, et al. Exp Mol Med. 2019 Jun 20;51(6):1-17. doi: 10.1038/s12276-019-0230-6. Exp Mol Med. 2019. PMID: 31221981 Free PMC article. Review.
Recent studies on mutations in cancer genomes have distinguished driver mutations from passenger mutations, which occur as byproducts of cancer development. The cancer genome atlas (TCGA) project identified 299 genes and 24 pathways/biological processes that …
Recent studies on mutations in cancer genomes have distinguished driver mutations from passenger mutations, which occur as byproducts …
Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?
Swaminathan M, Bourgeois W, Armstrong SA, Wang ES. Swaminathan M, et al. Cancer J. 2022 Jan-Feb 01;28(1):62-66. doi: 10.1097/PPO.0000000000000571. Cancer J. 2022. PMID: 35072375 Review.
KMT2Ar acute leukemias constitute 5% to 10% of acute leukemias, and NPM1 mutations are identified in 30% of newly diagnosed acute myeloid leukemias (AMLs). ...Preliminary results in relapsed/refractory NPM1 mutant and KMT2Ar AML have shown on-target effects, tolerab …
KMT2Ar acute leukemias constitute 5% to 10% of acute leukemias, and NPM1 mutations are identified in 30% of newly diagnosed acute mye …
2,572 results